Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trialRussell E. Ware, Robert J. Adams, Barry R. Davis et al.|The Lancet|2015Cited by 518
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History StudyRachael F. Grace, Wilma Barcellini, Yaddanapudi Ravindranath et al.|Blood|2018Cited by 165
Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History StudyEduard J. van Beers, Rachael F. Grace, Stephanie van Straaten et al.|Haematologica|2018Cited by 61
The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiencyHanny Al‐Samkari, Rachael F. Grace, Kathryn Addonizio et al.|British Journal of Haematology|2020Cited by 22
TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell AnemiaRussell E. Ware, Robert J. Adams, Barry R. Davis et al.|Blood|2015Cited by 17